Lexicon Pharmaceuticals (LXRX) News Today $1.42 +0.02 (+1.43%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.34%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from AnalystsOctober 18, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (LXRX) Presents at Arrowhead's 19th Annual Pain Therapeutics Summit - SlideshowOctober 15, 2025 | seekingalpha.comLexicon presents additional pilavapadin data in DPNPOctober 14, 2025 | msn.comLexicon Pharmaceuticals: Promising Phase 2b Results and Strategic Plans Justify Buy RatingOctober 14, 2025 | tipranks.comLexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics SummitOctober 14, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200-Day Moving Average - Here's What HappenedOctober 14, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% Higher - What's Next?October 10, 2025 | marketbeat.comLexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3% - Time to Sell?October 8, 2025 | marketbeat.comLexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain ManagementOctober 8, 2025 | quiverquant.comQLexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic PainOctober 8, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street ZenOctober 4, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc.September 30, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 ...September 24, 2025 | finanznachrichten.deLexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmASeptember 24, 2025 | marketbeat.comLexicon expects delay in FDA feedback on additional data for its diabetes drugSeptember 23, 2025 | reuters.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 23, 2025 | marketbeat.comLexicon reports FDA's decision to extend review period for ZynquistaSeptember 23, 2025 | msn.comLexicon Pharmaceuticals Provides Update on Zynquista NDA Resubmission Following FDA FeedbackSeptember 22, 2025 | quiverquant.comQLexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 DiabetesSeptember 22, 2025 | globenewswire.comPilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of ...September 17, 2025 | finance.yahoo.comLexicon announces presents data from Phase 2 PROGRESS study for pilavapadinSeptember 17, 2025 | msn.comLexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy RatingSeptember 17, 2025 | tipranks.comLexicon Pharmaceuticals Presents Promising Phase 2b Results for Pilavapadin in Treating Diabetic Peripheral Neuropathic PainSeptember 17, 2025 | quiverquant.comQPilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual MeetingsSeptember 17, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200 Day Moving Average - Here's WhySeptember 17, 2025 | marketbeat.comLexicon Pharmaceuticals Presents Promising Data on Pilavapadin for Diabetic Peripheral Neuropathic Pain at Upcoming Medical MeetingsSeptember 11, 2025 | quiverquant.comQLexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical MeetingsSeptember 11, 2025 | globenewswire.comPromising Preclinical Data and FDA Alignment Support Buy Rating for Lexicon Pharmaceuticals’ PilavapadinSeptember 11, 2025 | tipranks.comLexicon submits additional data to FDA for benefit-risk profile of ZynquistaSeptember 8, 2025 | msn.comLexicon Pharmaceuticals Submits Additional Clinical Data for Zynquista NDA Resubmission Following FDA Complete Response LetterSeptember 8, 2025 | quiverquant.comQLexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 DiabetesSeptember 8, 2025 | globenewswire.comCiti Keeps Their Buy Rating on Lexicon Pharmaceuticals (LXRX)September 6, 2025 | theglobeandmail.comLexicon Pharmaceuticals (NASDAQ:LXRX) Given Buy Rating at HC WainwrightSeptember 4, 2025 | marketbeat.comLexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025September 4, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comLexicon Pharmaceuticals to Present Patient Insights on Diabetic Peripheral Neuropathic Pain at PAINWeek 2025September 3, 2025 | quiverquant.comQLexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025September 3, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc. $LXRX Holdings Trimmed by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comLexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy RatingSeptember 2, 2025 | tipranks.comSotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented ...September 2, 2025 | markets.businessinsider.comSotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 CongressSeptember 2, 2025 | globenewswire.comSiren L.L.C. Cuts Stake in Lexicon Pharmaceuticals, Inc. $LXRXAugust 31, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Moderate Buy" from AnalystsAugust 31, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above 200-Day Moving Average - Here's WhyAugust 29, 2025 | marketbeat.comLexicon Pharmaceuticals to Participate at Two Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comLexicon Pharmaceuticals: Strategic Retrenchment Likely To Take Years To Show ResultsAugust 25, 2025 | seekingalpha.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200-Day Moving Average - What's Next?August 20, 2025 | marketbeat.comLeerink Partnrs Brokers Increase Earnings Estimates for LXRXAugust 11, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Raised to $1.90 at CitigroupAugust 8, 2025 | marketbeat.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.830.85▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼25▲LXRX Articles Average Week Get the Latest News and Ratings for LXRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lexicon Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CLDX News MNKD News BCRX News NVAX News OPK News DVAX News ZBIO News INVA News GERN News MYGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
